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events in patients with end-stage renal disease.
Background. Plasma asymmetric dimethylarginine
(ADMA), an endogenous inhibitor of nitric oxide syn-
thase (NOS), is an independent predictor of overall mortality
and cardiovascular outcome in hemodialysis patients. However,
not only ADMA but also traditional risk factors account for
only part of the high cardiovascular morbidity and mortality in
these patients. We investigated cross-sectionally the association
between coupling factor 6 (CF6), an endogenous inhibitor
of prostacyclin synthesis, and cardiovascular events in 95
hemodialysis patients.
Methods. Plasma CF6 level was measured by radioim-
munoassay, whereas plasma ADMA level by high-performance
liquid chromatography (HPLC).
Results. Plasma levels of CF6 and ADMA were threefold
higher in hemodialysis patients than in control individuals, and
there was a positive correlation between these two compounds
(r = 0.25, P < 0.05). Plasma CF6 level was positively corre-
lated with serum creatinine level (r = 0.36, P < 0.01) and was
reduced after dialysis (P < 0.05). Plasma CF6 and ADMA lev-
els were both higher in hemodialysis patients complicating is-
chemic heart disease (myocardial infarction and/or angina) than
in those free of cardiovascular events. In a multiple regression
model, plasma CF6 level (r = 0.24, P = 0.023) and ADMA
level (r = 0.26, P = 0.023) were independently related to the
occurrence of ischemic heart disease in hemodialysis patients.
Conclusion. CF6 is a novel risk factor for ischemic heart
disease in end-stage renal disease (ESRD). Synergism of this
peptide and ADMA might contribute to its occurrence pre-
sumably by inhibition of prostacyclin and nitric oxide produc-
tion. A prospective study is needed to evaluate this issue more
precisely.
Key words: coupling factor 6, asymmetric dimethylarginine, end-stage
renal disease, cardiovascular event.
Received for publication January 7, 2003
and in revised form June 23, 2003
Accepted for publication July 30, 2003
C© 2003 by the International Society of Nephrology
Cardiovascular disease is a major cause of death in
patients with end-stage renal disease (ESRD). The pro-
jected life expectancy of patients on dialysis is 20% to
25% of that of the general population [1]. Although pa-
tients with ESRD commonly have associated diseases
that have a high cardiovascular risk in themselves, such
traditional risk factors account for only parts of the
high cardiovascular morbidity and mortality in these pa-
tients [1]. A recent prospective study showed that plasma
asymmetric dimethylarginine (ADMA), an endogenous
inhibitor of nitric oxide synthase (NOS), was an inde-
pendent predictor of overall mortality and cardiovascular
outcome in hemodialysis patients [2]. The plasma ADMA
level was reported to be two to six times higher in uremic
patients than in healthy control individuals [3–5], and to
be higher in dialysis patients with clinically manifested
atherosclerosis than in those without atherosclerotic dis-
ease [5]. However, this compound could not account fully
for the high cardiovascular morbidity and mortality.
Recently, coupling factor 6 (CF6), an essential com-
ponent of the energy-transducing stalk of mitochondrial
adenosine triphosphate (ATP) synthase [6], was found
as a novel endogenous inhibitor of prostacyclin synthesis
[7]. It was identified while investigating the mechanism
of suppression of prostacyclin in spontaneously hyper-
tensive rats (SHR). Levels of circulating prostacyclin in
SHR were decreased compared with those in normoten-
sive control, despite the fact that, as measured in iso-
lated aortic strips, prostacyclin generation was elevated
in SHR [8, 9]. We showed that CF6 suppresses cytoso-
lic phospholipase A2 in vascular endothelial cells [7] and
functions as an endogenous vasoconstrictor in the fashion
of a circulating hormone [10]. We hypothesized that CF6
is not excreted in patients with chronic renal failure, and
its plasma concentration is increased in uremic patients.
Thus, accumulation of CF6 might be a novel cardiovas-
cular risk factor in ESRD. In this study, we investigated
the association between CF6 and cardiovascular events
in patients with ESRD.
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METHODS
Subjects
This study protocol was approved by the Ethics Com-
mittee of the University Hospital, and was performed
after informed consent was obtained from each subject.
Ninety-five patients with ESRD (52 men and 43 women
with a mean age of 58 years) who had undergone regu-
lar dialysis treatment for at least 6 months and without
clinical evidence of circulatory congestion were investi-
gated. The patients were treated with standard dialysis
three times a week. The quantity of blood was 170 ±
3 mL/min, and the quantity of dialysate was all
500 mL/min. The duration of dialysis was 3.8 ± 0.1 hours.
Dialyzer used in this study was polysulfone (53%),
polymethylmethacrylate (41%), and vitamin E-coated
polysulfone (6%). Kt/V was 1.13 ± 0.03. Dry weight
was targeted in every patient to achieve a normoten-
sive edema-free state. Blood was drawn at a midweek
interval for the measurements of plasma levels of CF6,
ADMA, and biochemical items after 20 to 30 minutes of
quiet resting in a semirecumbent position prior to dialy-
sis treatment. In ten patients, blood was also drawn for
the measurement of CF6 level after dialysis treatment. In
only eight patients, urine was excreted once a few days
(the average of daily volume <200 mL) and was collected
for the measurement of CF6 level. Cardiovascular risk
factors and cardiovascular events were assessed in each
subject. The diagnosis of stroke was made according to
the World Health Organization criteria: rapidly devel-
oping clinical signs of focal or global loss of cerebral
function with symptoms lasting more than 24 hours,
with no apparent cause other than vascular origin. All
patients underwent computed tomography scanning to
define the type and site of stroke. The diagnosis of
angina was made by transient chest pain typical of angina
and horizontal ST segment depression >1.0 mm on ≥2
leads after exercise testing or during spontaneous chest
pain attack in the ECG. The diagnosis of acute my-
ocardial infarction (AMI) was made by persistent chest
pain typical of AMI, ST segment elevation >1.0 mm
on ≥2 leads, and elevation of cardiac enzymes. The
diagnosis of arrhythmia, most of which was atrial fib-
rillation, was made by the ECG. The diagnosis of
peripheral artery disease was made by its typical symp-
tom and digital pulse volume recording. The diagnosis
of retinal vein thrombosis was made by a dilated fundus
examination.
In another group of 13 patients with chronic renal fail-
ure who did not undergo maintenance dialysis (ten men
and three women with a mean age of 58 years), blood was
drawn for the measurement of CF6. In 27 control subjects
with normal renal function (15 men and 12 women with
a mean age of 51 years), blood and urine were collected
for the measurement of CF6.
Radioimmunoassay for CF6
Sep-Pak C18 cartridges loaded with plasma or urine
acidified with HCl. After washing with water, the ab-
sorbed materials were eluted with 60% acetonitrile con-
taining 0.1% trifluoroacetic acid (TFA) and submitted
to radioimmunoassay (RIA). The standard recombinant
CF6, which was obtained from Escherichia coli using a
cleavable fusion protein strategy [11], or the unknown
samples was incubated with anti-CF6 antiserum dilu-
ent (1:1200) for 12 hours, and then the tracer solution
(18,000 to 20,000 cpm) was added. After incubation for
24 hours, antirabbit IgG goat serum diluent contain-
ing 10% polyethylene glycol 6000 and rabbit IgG were
added and radioactivity of the precipitate was measured
in gamma counter.
Half-maximum inhibition of radioiodinated ligand
binding by human recombinant CF6 was observed at
300 pg/tube. An appropriate amount of cold recombinant
CF6 added to the RIA sample was precisely determined
by the present RIA. The intra- and interassay coefficients
of variance were 8.0% and 10.2%, respectively.
The immunoreactive substances present in the hu-
man urine were characterized by high-performance liq-
uid chromatography (HPLC). The samples, treated with
a Sep-Pak C18 cartridge, were applied on reverse-phase
HPLC using an Inertsil ODS-2 C18 column (4.6 ×
250 mm) (GL Science, Inc. Tokyo, Japan) and were fol-
lowed by linear gradient of acetonitrile ranging from 20%
to 60% over 30 minutes at a flow rate of 1 mL/min.
Synthesis of antibody for CF6
Synthetic CF6 fragment (human Cys-10-27 amino
acid) solution was emulsified with an equal volume of
Freund’s complete adjuvant, and used for immuniz-
ing New Zealand white rabbits. The cross-reactivity of
anti-CF6 antibody and the characterization of immunore-
active substances present in the human plasma were
examined as previously.
Measurement of ADMA
Plasma ADMA level was measured by HPLC, as
previously described [12]. Briefly, plasma (1 mL) was
mixed with 2 mL of 10% trichloroacetic acid, put on
ice for 10 minutes, and centrifuged at 2500g for 15 min-
utes. The resulting supernatant was evaporated in vacuo
to dryness, and was then loaded to a Bond Elut PRS
column. After washing with 10 mL of 1 mol/L pyri-
dine, ADMA was eluted by 10 mL of 3 mol/L ammo-
nia and evaporated in vacuo to dryness. The extract
was incubated with 20 lL phenylthiocarbamoyl solution
(ethanol:triethylamine:water:phenyl isothiocyanate =
7:1:1:1, vol/vol) for 20 minutes at room temperature. The
dried samples were applied on reverse-phase HPLC using
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a YMC-Pack ODS-AM column (YMC Co., Kyoto, Japan)
and 60 mmol/L acetic buffer (pH 6.6)/0.05% TFA elution
with a linear gradient of acetonitrile ranging from 6% to
60% over 25 minutes at 1 mL/min flow rate. Amounts of
ADMA in the medium were estimated from a standard
curve of synthetic ADMA.
Analysis of other variables
Serum sodium and potassium ion levels were mea-
sured with a flame photometer. Serum uric acid, glucose,
albumin, calcium, phosphate, and creatinine levels and
hemoglobin were measured by an autoanalyzer method.
Plasma nitrate + nitrite (NOx) level was measured by the
Griess method using NOx colorimetric assay kit (Cayman
Chemical Co). Briefly, nitrate was converted to nitrite
with cofactor and nitrate reductase, and total nitrite was
measured at 540 nm absorbance by reaction with Greiss
reagent. Von Willebrand factor was measured by risto-
cetin agglutination method (SRL,Tokyo, Japan).
Statistics
Values are shown as mean ± one standard error (SE).
Differences of mean values were assessed by a paired or
unpaired Student t test for comparison of two variables
and by an analysis of variance (ANOVA) for comparison
for multiple variables. Relationships between two con-
tinuous variables were assessed by a regression analysis
using the Pearson correlation coefficient. Differences in
items were analyzed by chi-square test or Fisher’s exact
probability test. A P value less than 0.05 was considered
statistically significant.
RESULTS
Patient profiles
Table 1 shows the baseline characteristics of the pa-
tients with ESRD. Cyclooxygenase inhibitor was daily
administered in five patients with ESRD. Hypertension
was present in 79%, diabetes mellitus in 24%, and hyper-
lipidemia in 4%. Of all patients, 87 showed anuria.
Relationship between CF6 and cardiovascular events
Plasma CF6 level was 33.2 ± 0.9 ng/mL in patients
with ESRD. Ninety-three (98%) patients had CF6 levels
above the upper limit of the normal range (<16 ng/mL).
The level in patients with chronic renal failure and with-
out maintenance dialysis was 21.9 ± 1.3 ng/mL, and was
higher than that in control subjects (12.8 ± 0.5 ng/mL)
but lower than that in patients with dialysis (both P <
0.05). The plasma CF6 level was significantly reduced af-
ter dialysis from 41.2 ± 4.2 ng/mL to 34.3 ± 2.4 ng/mL
(N = 10, P < 0.05). By univariate analysis, plasma CF6
level was positively correlated with serum creatinine level
Table 1. Characteristics of subjects
Total population (N = 95)
Demographic
Age years 57.8 ± 13.7
Gender men/women 52/43
Cardiovascular risk factors
Hypertension 79%
Diabetes mellitus 24%
Hyperlipidemia 4%
Biochemical
Serum sodium mmol/L 140.1 ± 3.1
Serum potassium mmol/L 4.4 ± 0.7
Serum calcium mg/dL 9.7 ± 1.3
Serum phosphate mg/dL 5.0 ± 1.4
Serum glucose mg/dL 120 ± 60
Serum albumin g/dL 3.7 ± 0.4
Serum uric acid mg/dL 5.8 ± 1.3
Hemoglobin g/dL 10.4 ± 1.7
Low-density lipoprotein 100.0 ± 3.7
cholesterol mg/dL
Renal function
Urination +/− 8/87
Variable is shown as mean ± one standard deviation.
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Fig. 1. Relationship between plasma coupling factor 6 (CF6) level and
serum creatinine concentration in patients with end-stage renal disease
(ESRD).
(r = 0.36, P < 0.01) (Fig. 1), but was not correlated with
duration of dialysis treatment and serum albumin level.
There was no correlation between plasma CF6 level and
Kt/V.
Urinary CF6 level was 112.6 ± 33.8 ng/mg creatinine
in control subjects. In most patients with ESRD, urine
was not excreted. In eight patients with urine excretion,
urinary CF6 level was 192.7 ± 18.6 ng/mg creatinine, but
the daily urine volume was <200 mL in all patients. Im-
munoreactive CF6 in the urine emerged at 5-minute frac-
tion and was not identical to that of authentic human CF6
(22 minutes).
Sixty-six cardiovascular events were observed in 51 pa-
tients (Table 2). They included three myocardial infarc-
tions, 11 strokes, 20 anginas, 14 congestive heart failures,
16 arrhythmias (mainly atrial fibrillation), one peripheral
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Table 2. Cardiovascular events in patients with end-stage renal
disease (ESRD)
Cardiovascular events Number of patients (N D 95)
Angina 20 (21%)
Arrhythmia 16 (17%)
Congestive heart failure 14 (15%)
Stroke 11 (12%)
Myocardial infarction 3 (3%)
Peripheral artery disease 1 (1%)
Retinal artery thrombosis 1 (1%)
Total 66 (69%)
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Fig. 2. Relationship between plasma coupling factor 6 (CF6) level and
cardiovascular events in patients with end-stage renal disease (ESRD).
Abbreviations are: IHD, ischemic heart disease (myocardial infarction
plus angina); CHF, congestive heart failure.
artery disease, and one retinal artery thrombosis. Plasma
CF6 level was higher in patients complicating ischemic
heart disease (myocardial infarction and/or angina) than
in those free of cardiovascular events (37.2 ± 1.9 ng/mL
vs. 30.8 ± 1.3 ng/mL, P < 0.05) (Fig. 2).
Von Willebrand factor was positively correlated with
plasma CF6 level in dialysis patients (N = 12) (r = 0.58,
P < 0.05), whereas plasma NOx level was negatively cor-
related with plasma CF6 level (N = 16) (r = −0.51, P <
0.05).
Relationship between ADMA and cardiovascular events
Plasma ADMA level was 3.04 ± 0.38 lmol/L in pa-
tients with ESRD. All patients had ADMA level above
the upper limit of the normal range (<1.16 lmol/L). By
univariate analysis, plasma ADMA level was positively
correlated with duration of dialysis treatment (r = 0.29,
P < 0.02) (Fig. 3), but was not correlated with serum cre-
atinine or albumin level. Plasma ADMA level was sig-
nificantly higher in patients complicating either ischemic
heart disease (4.34 ± 0.75 lmol/L) or arrhythmia (4.28 ±
0.90 lmol/L) than in those free of cardiovascular events
(2.78 ± 0.15 lmol/L, both P < 0.05) (Fig. 4).
CF6, ADMA, and traditional risk factors
in cardiovascular events
In a multiple regression model, plasma levels of CF6
(r = 0.237, P = 0.023) and ADMA (r = 0.256, P = 0.0226)
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Fig. 3. Relationship between plasma asymmetric dimethylarginine
(ADMA) level and duration of dialysis treatment (month) in patients
with end-stage renal disease (ESRD).
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Fig. 4. Relationship between plasma asymmetric dimethylarginine
(ADMA) level and cardiovascular events in patients with end-stage
renal disease (ESRD). Abbreviations are: IHD, ischemic heart disease
(myocardial infarction plus angina); CHF, congestive heart failure.
were independently related to the occurrence of ischemic
heart disease in patients with ESRD. However, none of
traditional risk factors, such as hypertension, diabetes
mellitus, and hyperlipidemia, was significantly related
to the occurrence of ischemic heart disease in dialysis
patients.
Relationship between CF6 and ADMA
and its implications
As shown in Figure 5, plasma level of CF6 was pos-
itively correlated with that of ADMA in patients with
ESRD (r = 0.25, P < 0.05).
The patients with higher plasma levels of CF6
(≥33 ng/mL) and ADMA (≥3 lmol/L) had a greater
number of cardiovascular events compared to those with
lower plasma levels of CF6 (<33 ng/mL) and ADMA
(<3 lmol/L) [15 events in 20 patients (75%) vs. 13 events
in 29 patients (45%), P < 0.05 by chi-square test]. The pa-
tients with higher plasma levels of both compounds also
tended to have a greater number of cardiovascular events
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Fig. 5. Relationship between plasma coupling factor 6 (CF6) level and
plasma asymmetric dimethylarginine (ADMA) level in patients with
end-stage renal disease (ESRD).
than those with higher ADMA level and lower CF6 level
[11/22 (50%), P = 0.096] and those with lower ADMA
level and higher CF6 level [11/24 (46%), P = 0.069].
DISCUSSION
The present study showed that plasma levels of CF6
and ADMA were threefold increased in patients with
ESRD, that plasma levels of CF6 and ADMA were both
higher in patients complicating ischemic heart disease
(myocardial infarction and/or angina) than in those free
of cardiovascular events by the cross-sectional retrospec-
tive observation, and that in a multiple regression model,
plasma levels of CF6 and ADMA were independently
related to the occurrence of ischemic heart disease.
CF6 as a cardiovascular risk factor in ESRD
Traditional cardiovascular risk factors, such as hyper-
tension, hypercholesterolaemia, diabetes, and smoking,
are often present in patients with ESRD. However, these
cardiovascular risk factors only partly account for in-
creased cardiovascular events in ESRD [1]. Prostacyclin
exerts a number of profound effects, including inflamma-
tion, thrombogenesis, cell growth, and peripheral circula-
tion [13], and its effect is widespread because prostacyclin
receptor is localized in various sites such as heart, aorta,
liver, kidney, and brain [14]. Endothelial dysfunction
occurs before the onset of overt vascular disease, and the
reduced generation of prostacyclin, which has an impor-
tant role in the regulation of renal function in health and
disease, might contribute to progression of cardiovascu-
lar disease. Indeed, we showed that plasma NOx level,
a marker of endothelial function, was negatively corre-
lated with plasma CF6 level, and von Willebrand factor, a
marker of endothelial damage, was positively correlated
with plasma CF6 in patients with ESRD.
The present study showed that plasma CF6 level was
threefold higher in patients with ESRD, and was signif-
icantly higher in dialysis patients complicating ischemic
heart disease than in those free of cardiovascular events
by the cross-sectional retrospective observation. In a
multiple regression model, plasma CF6 level was inde-
pendently related to the occurrence of ischemic heart
disease despite the fact that hypertension, diabetes mel-
litus, and hyperlipidemia were not significantly related to
that of ischemic heart disease in ESRD. Thus, these find-
ings seem to support the hypothesis that accumulation of
CF6 may be a novel cardiovascular risk factor, especially
for ischemic heart disease, in patients with ESRD. These
also suggest that ESRD and atherosclerotic vascular dis-
ease could be independently associated with the increase
in the plasma level of CF6.
It is unclear whether the higher level of CF6 may be
related to the genesis of ischemic heart disease or sec-
ondary to ischemic heart disease in patients with ESRD.
However, it is noted that in these patients, not only the
plasma level of CF6 but also that of ADMA was re-
markably elevated compared with healthy control indi-
viduals. In patients with higher plasma levels of ADMA
(≥3 lmol/L) and CF6 (≥33 ng/mL), incidence of cardio-
vascular events tended to be greater than in those with
higher level of ADMA and lower level of CF6 or those
with lower level of ADMA and higher level of CF6. Thus,
synergism of these compounds might play an important
role in the occurrence of ischemic heart disease presum-
ably via inhibition of prostacyclin and nitric oxide pro-
duction. Plasma CF6 level was not correlated with Kt/V
but was positively correlated with serum creatinine level.
Dialysis treatment slightly but significantly reduced the
plasma level of CF6. These suggest that modulation of
serum creatinine level by dialysis treatment might be
beneficial to prevent the occurrence of cardiovascular
accidents.
The high level of plasma CF6 in patients with ESRD
might be caused by no excretion or markedly reduced
urine. This is indicated by our findings that plasma CF6
level was greater in patients with chronic renal fail-
ure without dialysis treatment than in control subjects,
and was further increased in patients with ESRD. In-
deed, metabolites of CF6 were excreted to the urine at
∼100 ng/mg creatinine in control subject, whereas no
excretion to the urine was found in most patients with
ESRD. Another possible explanation for the high level
of plasma CF6 is that the generation of CF6 is enhanced
in patients with ESRD. We previously showed that shear
stress stimulates the gene expression and release of CF6
in human vascular endothelial cells [15]. Thus, a hyper-
volemic state in ESRD might be involved in the eleva-
tion of plasma CF6. Because CF6 is synthesized in an
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immature form in the cytosol and accumulated within
the mitochondria [16], tissue injury or apoptosis could
enhance its release into the systemic circulation. Indeed,
apoptosis was reported to be enhanced in aorta and left
ventricle obtained from the animal models of ESRD [17].
ADMA as a cardiovascular risk factor in ESRD
The endothelium in patients with ESRD is dysfunc-
tional, as suggested by findings of several clinical studies
[18, 19], but the mechanism underlying this defect is not
fully understood. Kari et al [18] found that endothelial
dysfunction in uremic children was related to the plasma
ADMA level. Hand, Haynes, and Webb [19] showed that
endothelial dysfunction was reversed after hemodialy-
sis sessions. Therefore, accumulation of ADMA might
explain endothelial dysfunction in patients with ESRD.
In the present study, we showed that plasma ADMA
level was higher in patients complicating ischemic heart
disease and/or arrhythmia than in those free of car-
diovascular events by the cross-sectional retrospective
observation. These findings may be consistent with those
of the recent prospective study showing that accumula-
tion of ADMA is an important risk factor for cardio-
vascular disease in chronic renal failure. Recently, in
patients with chronic atrial fibrillation, plasma NOx level
was reported to be decreased [20]. Our finding that the
plasma ADMA level was elevated in patients complicat-
ing arrhythmia, mostly atrial fibrillation, may explain the
pathogenesis of reduced nitric oxide generation in atrial
fibrillation. This issue remains to be elucidated.
In individuals at high risk of cardiovascular disease or
with overt atherosclerotic vascular disease, ADMA level
is associated with degree of endothelial dysfunction and
with the reduction in nitric oxide elaboration [21, 22].
Kielstein et al [5] observed that plasma ADMA level was
higher in patients with ESRD and atherosclerotic vascu-
lar disease than in those without vascular complications.
These investigators suggested that ESRD and atheroscle-
rotic vascular disease could independently cause ADMA
level to rise in patients with ESRD.
Relationship between CF6 and ADMA
It is unknown whether a crosstalk is present between
CF6 and ADMA in ESRD. We recently found that
plasma nitric oxide level is negatively correlated with
plasma CF6 level in patients with essential hypertension.
Therefore the lower plasma level of nitric oxide due to
the higher plasma level of ADMA may increase CF6.
Indeed, this study clearly showed that in patients with
ESRD, plasma NOx level was negatively correlated with
plasma CF6 level. Alternatively, the decrease in prosta-
cyclin per se or its second messenger cyclic adenosine
monophosphate (cAMP) may influence ADMA gener-
ation and degradation via modulating protein arginine
methyltransferase type 1 and dimethylarginine dimethy-
laminohydrolase activities. In ESRD, not only the pro-
duction of reactive oxygen species but also shear stress
to vascular endothelial cells is enhanced, and both of
them could increase the plasma levels of these inhibitory
compounds. Therefore, it seems possible that CF6 and
ADMA are both increased independently by the com-
mon stimuli despite of no crosstalk between them.
In humans, traditional risk factors such as hyper-
tension [23], hypercholesterolemia [24], and diabetes
mellitus [25] are associated with elevated ADMA level,
which causes impaired endothelium-dependent vasodi-
lation. The elevated ADMA may in turn increase the
plasma level of CF6 via endothelial dysfunction. These
suggest that traditional risk factors also may contribute
to the higher plasma levels of ADMA and CF6.
CONCLUSION
This report shows that CF6 may be a novel cardiovas-
cular risk factor in ESRD by the cross-sectional retro-
spective observation. In light of the current findings, it
appears that CF6 is associated with the occurrence of is-
chemic heart disease in patients with ESRD. These data
raise the possibility of a new explanation for a high car-
diovascular risk in ESRD, and pathologic role of CF6 may
be expected to be growing. Since the data of the present
study was derived from the cross-sectional retrospective
observation, we need a prospective study to evaluate this
issue more precisely.
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